Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs
Executive Summary
Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.